The latest news and views from bridge therapeutics

12/07/17 Let’s fix the cause, rather than the problem, of opioid addiction

A recent article published on the website The Hill discusses the problem of prescribing addictive schedule III drugs for pain relief rather than the equally effective and non-addictive schedule II drugs, see full article here.


05/19/17 Fourteen things Trump needs to know about opioids

As President Trump promises to fight the opioid epidemic, here are 14 things experts want him to know

May 11, 2017

Greg Sullivan, MD, Chief Scientific Officer & CEO of Bridge Therapeutics, recently spoke with Managed Healthcare Executive for a special report entitled, “Fourteen things Trump needs to know about opioids.” Managed Healthcare Executive is read by 40,000 C-suite executives across the country at health plans and pharmacy benefit managers (PBMs).

Dr. Sullivan discussed with Managed Healthcare Executive managing editor Tracey Walker how the lack of non-addictive medications for long-term pain has left the 25 million chronic pain patients with no safe options to treat their condition, which means many of them are addicted to dangerous forms of opioids. “The tolerance that develops from traditional opioids reduces the analgesic effects of the medication, causing the patient to require a higher dose to achieve the same level of pain relief,” Dr. Sullivan said. “Compared with traditional full agonist opioids, buprenorphine affects the receptors in the brain responsible for euphoria to a lesser degree, decreasing the potential for addiction.”

He added: “Of all the opioids that have been approved for chronic pain, only buprenorphine has been demonstrated to be safe for long-term use, while not causing tolerance. It’s important to note that buprenorphine is effective in treating certain types of pain, but not inflammatory pain—it must be used in conjunction with an NSAID to effectively treat chronic pain.”

Read the full article here

05/19/17 Bridge Therapeutics to Present at BioTrinity 2017 Conference in London

CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives

May 10, 2017

(PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 11th year, draws attendees from approximately 30 countries and includes more than 1,000 delegates, dozens of exhibitors, and industry leaders from investment firms and global pharma.

Dr. Sullivan’s presentation to key investors and senior industry executives focused on the story of Bridge Therapeutics and its investigational drug compound BT-205, a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.

Read more

For more information about Bridge Therapeutics please contact us today using the form below.